Cart
sales@molnova.com
Regorafénib N-oxyde (M2)
CAS No. 835621-11-9
Regorafénib N-oxyde (M2)( —— )
Catalog No. M24825 CAS No. 835621-11-9
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 48 | In Stock |
|
| 5MG | 69 | In Stock |
|
| 10MG | 100 | In Stock |
|
| 25MG | 180 | In Stock |
|
| 50MG | 317 | In Stock |
|
| 100MG | 461 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRegorafénib N-oxyde (M2)
-
NoteResearch use only, not for human use.
-
Brief DescriptionRegorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1.
-
DescriptionRegorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1 (IC50s: 13/4.2/46, 1.5, 22, 7, and 2.5 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDGFR
-
RecptorVEGFR1|VEGFR2|VEGFR3|PDGFRβ|RET|Kit|Raf-1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number835621-11-9
-
Formula Weight498.81
-
Molecular FormulaC21H15ClF4N4O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCNC(=O)C1=[N+](C=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F)[O-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Allard M, et al. Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS. J Pharm Biomed Anal. 2017 Aug 5;142:42-48.
molnova catalog
related products
-
BTZ043
BTZ043 is a DprE1 inhibitor with nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro.
-
Sunitinib
A multi-targeted RTK inhibitor that targets VEGFR2 (Flk-1) and PDGFRβ with Ki of 8 nM and 9 nM respectively.
-
Toceranib
Toceranib phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively), has antitumor and antiangiogenic activity.
